Buy FEMY by Aug 20, 2026.

Current price 2.65. Resistance 3.48 **Femasys Announces FDA Approval of Modular PMA Submission Approach for FemBloc** Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator developing transformative fertility and non-surgical permanent birth control solutions designed to improve the standard of care, expand access, and reduce costs for women worldwide, announced today that the U.S. Food and Drug Administration has approved the Company's modular premarket approval application (PMA) pathway for FemBloc, its investigational non-surgical permanent birth control technology in the United States. …